RPG Life Sciences Launches Naprosyn ES in Strategic Partnership

The Mumbai-based pharma firm partners with Archerchem Healthcare to introduce an advanced pain-management solution to the Indian market.

MUMBAI — RPG Life Sciences (RPG LS) announced on Monday, July 13, 2026, a strategic partnership with Archerchem Healthcare to launch Naprosyn ES across India. The new product, a combination of Naproxen and Esomeprazole, is designed to provide an effective anti-inflammatory solution while offering critical gastro-protection for patients requiring long-term therapy.

The launch marks a significant expansion of the existing business relationship between the two companies. Under the terms of the agreement, RPG Life Sciences will serve as the exclusive marketer and distributor of Naprosyn ES nationwide, while Archerchem Healthcare will act as the exclusive supplier.

Addressing Unmet Medical Needs

Naprosyn ES is formulated to meet a specific clinical requirement: helping patients who rely on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) manage pain without the common side effects of gastrointestinal distress. By combining the therapeutic benefits of Naproxen with the protective barrier of Esomeprazole, the drug aims to improve patient compliance and safety, particularly among the elderly and those with gastro-sensitive health profiles.

The combination was co-developed by Archerchem Healthcare and its development partners, reflecting a focus on differentiated formulations that offer better health outcomes than standard generic alternatives.

Strengthening the Branded Formulations Portfolio

This launch is part of RPG Life Sciences’ ongoing strategy to bolster its domestic formulations business. In its fiscal year 2026 performance report, the company highlighted a 13.8% year-on-year revenue growth in its domestic business, outperforming the broader Indian Pharmaceutical Market (IPM).

"At RPG Life Sciences, innovation is rooted in patient-centricity," stated Ashok Nair, Managing Director of RPG Life Sciences, during the announcement. The company has been aggressively expanding its presence in niche therapeutic areas—including nephrology, rheumatology, and oncology—where its flagship brand, Naprosyn, has already seen double-digit market-beating growth.

Official Sources

The partnership details were formally disclosed in a regulatory filing to the National Stock Exchange of India (NSE) and BSE Limited on July 13, 2026. The filing complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates the timely disclosure of material business agreements.

Why It Matters

The introduction of Naprosyn ES is expected to provide RPG Life Sciences with a competitive edge in the high-value chronic pain management segment. For patients, the development provides a safer, more convenient alternative to traditional multi-pill regimes. For investors, the partnership underscores the firm’s commitment to growing its high-margin branded formulations business, which remains a key pillar of its long-term strategy for market outperformance.

Key Facts at a Glance

• Product: Naprosyn ES (a combination of Naproxen and Esomeprazole).

• Partnership: RPG Life Sciences as the exclusive marketer/distributor; Archerchem Healthcare as the exclusive supplier.

• Therapeutic Focus: Safe, long-term NSAID therapy with gastro-protection.

• Strategic Goal: Expanding presence in the high-growth rheumatology and pain management segments.

FAQ

What is Naprosyn ES?

Naprosyn ES is a combination medication containing an anti-inflammatory (Naproxen) and a proton pump inhibitor (Esomeprazole) to protect the stomach during long-term pain management.

How does this partnership benefit RPG Life Sciences?

The partnership allows RPG LS to leverage its extensive marketing and distribution network to introduce a specialized, co-developed product, strengthening its position in the competitive domestic formulations market.

Who is the target patient group for this drug?

The drug is specifically designed for patients requiring long-term NSAID therapy, especially those at a higher risk of developing gastrointestinal complications.

Source: RPG Life Sciences Regulatory Filing (NSE), RPG Life Sciences Investor Relations